Midatech Pharma PLC (MTP): Price and Financial Metrics
GET POWR RATINGS... FREE!
MTP Stock Price Chart Interactive Chart >
MTP Price/Volume Stats
| Current price | $0.58 | 52-week high | $3.61 |
| Prev. close | $0.56 | 52-week low | $0.38 |
| Day low | $0.51 | Volume | 21,500 |
| Day high | $0.60 | Avg. volume | 59,462 |
| 50-day MA | $0.75 | Dividend yield | N/A |
| 200-day MA | $1.25 | Market Cap | 7.39M |
Midatech Pharma PLC (MTP) Company Bio
Midatech Pharma PLC focuses on the development and commercialization of multiple, high-value, targeted therapies for major diseases with high unmet medical need in the nanomedicine field.
Latest MTP News From Around the Web
Below are the latest news stories about Midatech Pharma Plc that investors may wish to consider to help them evaluate MTP as an investment opportunity.
Midatech Pharma PLC Announces Extension of Janssen collaboration re Q-SpheraMidatech announces extension of R&D collaboration with Janssen focused on Q-Sphera technologyABINGDON, UK / ACCESSWIRE / January 17, 2022 / Midatech Pharma PLC (AIM:MTPH)(NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, is pleased to announce the extension of its R&D collaboration with Janssen Pharmaceutica NV (Janssen) originally announced on 21 July 2020.On 17 June 2021, the Company announced that, using its Q-Sphera techno |
Midatech Pharma plc (NASDAQ: MTP) Stock Forecast: Downside Of -111583.69% By 2021The trading price of Midatech Pharma plc (NASDAQ:MTP) closed higher on Monday, December 13, closing at $1.41, 6.02% higher than its previous close. >> 7 Top Picks for the Post-Pandemic Economy |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayWelcome back, investor! |
Midatech Pharmas IND application for a Phase 1 study of MTX110 has been cleared by the US FDAMidatech Pharma PLC (LON:MTPH; Nasdaq: MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, has announced that its Investigational New Drug (IND) application for a Phase 1 study of MTX110, a panobinostat complex to be administered by convection enhanced delivery in patients with recurrent glioblastoma multiforme (rGBM), has been cleared by [] |
Midatech Pharma''s IND application for a Phase 1 study of MTX110 has been cleared by the US FDA - DirectorsTalk InterviewsMidatech Pharma''s IND application for a Phase 1 study of MTX110 has been cleared by the US FDA |
MTP Price Returns
| 1-mo | -22.67% |
| 3-mo | -41.88% |
| 6-mo | -60.70% |
| 1-year | -72.12% |
| 3-year | -92.66% |
| 5-year | -99.60% |
| YTD | -44.76% |
| 2021 | -43.85% |
| 2020 | -45.74% |
| 2019 | -55.53% |
| 2018 | -81.55% |
| 2017 | -69.57% |
Continue Researching MTP
Want to do more research on Midatech Pharma Plc's stock and its price? Try the links below:Midatech Pharma Plc (MTP) Stock Price | Nasdaq
Midatech Pharma Plc (MTP) Stock Quote, History and News - Yahoo Finance
Midatech Pharma Plc (MTP) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...